Skip to main content

Table 1 Patient demographics

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Characteristic

N = 17

Age, mean (range) years

50 (37–63)

Female

17 (100%)

Race

 Caucasian

9 (57%)

 African–American

8 (43%)

No. prior lines of systemic therapy

 

 0

9

 1

4

 2

4

Site of recurrence

 

 Locoregional

6

 Distant disease (bone, liver, lung, or brain)

11